Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011-Reference-Cited by-同舟云学术

Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011

Published:2015-08-11 Issue:6 Volume:314 Page:604
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Rathi Vinay K.¹,Krumholz Harlan M.²,Masoudi Frederick A.³,Ross Joseph S.⁴

Affiliation:

1. Yale University School of Medicine, New Haven, Connecticut2Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Connecticut

2. Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Connecticut3Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut4Robert Wood Johnson Foundation Cli

3. University of Colorado Anschutz Medical Campus, Aurora7Colorado Cardiovascular Outcomes Research Consortium, Denver

4. Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Connecticut4Robert Wood Johnson Foundation Clinical Scholars Program, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut5Department o

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reporting of Demographics & Subgroup Analyses in Premarketing Studies of FDA Approved High-Risk Cardiovascular Devices, 2014–2022;Medical Devices: Evidence and Research;2024-04

2. Lifecycle evaluation of medical devices: supporting or jeopardizing patient outcomes? A comparative analysis of evaluation models;International Journal of Technology Assessment in Health Care;2024

3. Physicians’ Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey;Health Affairs;2024-01-01

4. Quality and transparency of clinical evidence for high-risk cardiovascular medical devices: a long way to go;European Heart Journal;2023-11-30

5. Studies Of Prescription Digital Therapeutics Often Lack Rigor And Inclusivity;Health Affairs;2023-11-01